Viking Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$393.3M | -$150.9M | -$100.8M | -$70.4M | -$55.7M |
| Operating expenses | $393.3M | $150.9M | $100.8M | $70.4M | $55.7M |
| Cash from operations | -$278.7M | -$87.8M | -$73.4M | -$48.4M | -$47.6M |
| Share repurchases | — | — | — | $6.8M | — |
| Total assets | $715.7M | $908.3M | $368.5M | $168.5M | $210.7M |
| Total liabilities | $76.7M | $28.0M | $20.1M | $23.2M | $8.8M |
Shares outstanding 116.1M · Free float 91.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.